X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Four things for CMS to keep in mind as they implement changes to Part D

By Nicole Longo  |    June 7, 2023
The Inflation Reduction Act (IRA) makes significant changes to Part D’s benefit structure and coverage, which will require careful policy development and thoughtful implementation. On Monday, PhRMA...   Read More

CMS guidance on IRA price setting process doubles down on bad policy

By Nicole Longo  |    April 14, 2023
As part of the implementation of the Inflation Reduction Act (IRA), the Centers for Medicare & Medicaid Services (CMS) issued draft guidance on the process for setting the price of medicines. The...   Read More

Medicare Part D open enrollment and what recent changes mean for beneficiaries

By Nicole Longo  |    November 17, 2022
It’s that time of year again: Medicare open enrollment! Seniors and people with disabilities who are newly eligible for Medicare, as well as current Medicare beneficiaries, can select or update their...   Read More

Many seniors are paying more for Part D medicines than their insurer

By Nicole Longo  |    October 18, 2022
For seniors who rely on Medicare Part D, the out-of-pocket costs for medicines can sometimes be a barrier. Insurers and pharmacy benefit managers (PBMs) continue to shift more and more costs to...   Read More

A key fact the White House is reluctant to admit

By Brian Newell  |    September 27, 2022
Today, President Biden delivered remarks that touch on recent drug pricing reforms included in the Inflation Reduction Act. While the law is deeply flawed and government price-setting is the wrong...   Read More

The Senate’s latest price setting proposal will undermine: Patient access to medicines

By Nicole Longo  |    July 26, 2022
Members of Congress continue to push a misguided drug pricing proposal under the guise of negotiation as part of the reconciliation package. This proposal is nothing short of government price setting...   Read More

Part D 101: Three charts show how the Medicare Part D program could be improved to work better for seniors and people with disabilities

By Gabby Migliara  |    April 27, 2022
In yesterday’s post, we learned how Medicare Part D works for seniors and people with disabilities. Unfortunately, Part D beneficiaries are increasingly facing higher out-of-pocket costs for the...   Read More

Part D 101: Three charts show how the program provides comprehensive prescription drug coverage

By Gabby Migliara  |    April 26, 2022
Medicare Part D provides prescription drug coverage for our nation’s seniors and Americans with disabilities. These beneficiaries can opt to enroll in Part D and pick from a variety of plans offered....   Read More

It’s a new year, but sadly Congress is still pursuing flawed price setting policies

By Nicole Longo  |    January 25, 2022
As we kick off 2022, Congress has a number of priorities they are aiming to tackle, including the Build Back Better Act (BBBA). Unfortunately, the bill includes policies that would take the...   Read More

Post-approval research save lives. Why is Congress trying disincentivize it?

By Andrew Powaleny  |    December 17, 2021
While some in Congress continue to claim the latest drug pricing plan in Washington is “negotiation,” that is far from the truth. The reality is that the current plan gives the government a new...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates